Kisspeptin-10
What it is, How it works, & What the Research Actually Shows 2026
Kisspeptin-10 is the peptide that sits at the very top of your body’s reproductive hormone chain — controlling testosterone, LH, and FSH production before any other hormone gets involved. It has real human clinical data behind it, a genuinely interesting mechanism, and a regulatory situation that has effectively closed off access in the US. This guide covers all three.
Key takeaways
- Kisspeptin-10 acts as the upstream trigger for testosterone, LH, and FSH production by activating GnRH neurons in the hypothalamus.
- In the primary human clinical trial (George et al., 2011), IV infusion raised testosterone from 16.6 to 24.0 nmol/L (P<0.001) and increased LH pulse frequency by 43%.
- Higher doses backfire. A 3 nmol/kg dose produced a weaker LH response than 1 nmol/kg, due to rapid receptor desensitization.
- The FDA’s PCAC voted unanimously on October 29, 2024 against including Kisspeptin-10 on the 503A bulks list. Compounding pharmacies cannot legally prepare it.
- The plasma half-life is approximately 4 minutes. Tachyphylaxis (loss of response) develops within 14 days of daily dosing.
What is Kisspeptin-10?
Kisspeptin-10 (KP-10) is a short peptide — just 10 amino acids long — that functions as the master upstream switch for reproductive hormone production.
It is derived from the KISS1 gene, which encodes a 145-amino acid precursor protein. That precursor gets cleaved into four active forms: Kisspeptin-54, Kisspeptin-14, Kisspeptin-13, and Kisspeptin-10. All four forms share the same C-terminal 10-amino acid sequence, which is the segment that binds to the receptor. Kisspeptin-10 is the shortest form with full biological activity.
A note on history: The KISS1 gene was first identified in 1996 — not as a reproductive hormone, but as a melanoma metastasis suppressor. Researchers discovered its role in reproduction later, when mutations in its receptor were found to prevent puberty entirely.
How does Kisspeptin-10 work?
Kisspeptin-10 does not act directly on the testes or ovaries. It works upstream, in the hypothalamus — triggering a hormonal chain reaction that ends with testosterone production.
The signaling chain:
Kisspeptin-10
→ binds KISS1R receptor on GnRH neurons
→ activates phospholipase C (PLC) and IP3-calcium cascade
→ GnRH neurons fire in pulses
→ pituitary releases LH and FSH
→ LH signals testes to produce testosterone
KISS1R (also called GPR54) is a G-protein coupled receptor located on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. Kisspeptin-10 fits into this receptor like a key into a lock, triggering the downstream signal.
The pulse generator
GnRH must be released in pulses to work correctly. Continuous GnRH actually shuts down the reproductive axis — which is exactly how GnRH agonist drugs like leuprolide suppress testosterone in prostate cancer treatment.
The timing of those pulses is controlled by a group of neurons in the arcuate nucleus of the hypothalamus called KNDy neurons. KNDy stands for the three neuropeptides they co-express: Kisspeptin, Neurokinin B, and Dynorphin.
- Neurokinin B stimulates KNDy neurons to fire
- Dynorphin acts as the brake
- Kisspeptin is the output signal that reaches GnRH neurons
Kisspeptin-10 restores pulsatile GnRH rather than producing a pharmacological surge. That distinction matters clinically.
Evidence grade: PeptideRx rates the evidence for Kisspeptin-10’s HPG axis stimulation as Grade B: limited human trials with strong mechanistic data and a well-characterized signaling pathway.
What does the research show?
Testosterone and male reproductive health
The first human clinical trial of Kisspeptin-10 (George et al., 2011; PMID 21632807) tested IV bolus doses from 0.01 to 3.0 mcg/kg in healthy men at the MRC Human Reproductive Sciences Unit, University of Edinburgh.
At the optimal bolus dose of 1 mcg/kg, LH rose from 4.1 to 12.4 IU/L within 30 minutes (P<0.001, n=6). At 3 mcg/kg, the LH response was weaker than at 1 mcg/kg (P<0.05). KISS1R desensitizes rapidly — pushing the dose higher produces diminishing returns.
Continuous IV infusion at 1.5 mcg/kg per hour over 9 hours:
- Increased LH pulse frequency from 0.7 to 1.0 pulses per hour (P<0.05)
- Tripled LH secretory burst mass from 3.9 to 12.8 IU/L per pulse (P<0.05)
At a higher infusion rate (4 mcg/kg per hour for 22.5 hours), testosterone rose from 16.6 to 24.0 nmol/L (P<0.001, n=4), and LH increased from 5.4 to 20.8 IU/L.
A proof-of-concept study in men with type 2 diabetes and low testosterone (George et al., 2013; PMID 23153270) showed Kisspeptin-10 infusion raised testosterone from 8.5 to 11.4 nmol/L (P=0.002) and increased LH pulse frequency from 0.6 to 0.9 pulses per hour (P=0.05).
How this differs from testosterone replacement therapy (TRT): TRT shuts down the body’s own LH production, causing testicular atrophy and suppressed sperm production. Kisspeptin-10 works upstream of that suppression — stimulating the body’s own hormonal cascade while preserving spermatogenesis.
Data gap: Some vendor protocols suggest 100–200 mcg subcutaneous injections 2–3 times per week to prevent testicular atrophy during TRT. No published clinical trial has validated this use. hCG remains the established option for maintaining testicular function during exogenous testosterone therapy.
Female fertility and hypothalamic amenorrhea
Hypothalamic amenorrhea (HA) — the loss of menstrual function due to suppressed GnRH pulsatility — accounts for over 30% of secondary amenorrhea cases. Caloric restriction, excessive exercise, and psychological stress are common causes.
Jayasena et al. (2009; PMID 19820030) administered subcutaneous Kisspeptin-54 to women with HA. On day 1, mean maximal LH increase was 24.0 IU/L. By day 14, the response had fallen to 2.5 IU/L — a roughly 90% reduction. The pituitary remained responsive to direct GnRH stimulation, confirming the desensitization occurs at the KISS1R level, not downstream.
Twice-weekly injections over 8 weeks partially preserved the LH response, with no further decline beyond day 14.
Cycle phase matters significantly in women. Healthy women in the follicular phase show minimal response even at high IV doses (10 nmol/kg). Women in the preovulatory and luteal phases respond with robust LH and FSH increases. This cycle-phase dependency is a major consideration for any clinical application.
Note on IVF applications: Kisspeptin-54 (not KP-10) has been studied as an IVF egg maturation trigger with lower ovarian hyperstimulation syndrome (OHSS) risk compared to hCG. Kisspeptin-10’s 4-minute half-life makes it impractical for IVF protocols.
Sexual desire: HSDD evidence
Two randomized controlled trials published in JAMA Network Open examined kisspeptin’s effects on hypoactive sexual desire disorder (HSDD). Both used Kisspeptin-54, not Kisspeptin-10.
In men (2023 RCT), kisspeptin-54 infusion increased penile tumescence by 56% in response to sexual stimuli. In women (2022 RCT), kisspeptin-54 deactivated frontal self-monitoring brain regions and increased subjective arousal scores. These findings suggest kisspeptin modulates limbic brain activity involved in sexual arousal — beyond its endocrine effects.
These results apply to the kisspeptin mechanism broadly. Kisspeptin-10 has not been directly tested in HSDD trials.
Data gap: Cancer and metastasis data is entirely preclinical. The KISS1 gene was originally identified as a metastasis suppressor, but no human oncology trials have been conducted with Kisspeptin-10 or Kisspeptin-54.
Kisspeptin-10 vs. alternatives
| Attribute | Kisspeptin-10 | Kisspeptin-54 | GnRH (gonadorelin) | hCG | MVT-602 |
|---|---|---|---|---|---|
| Plasma half-life | ~4 minutes | 27.6 minutes | 2–4 minutes | ~24–36 hours | Extended (Phase 2) |
| FDA status (2026) | Not approved; PCAC voted against 503A compounding (Oct 2024) | Not approved; research only | Gonadorelin approved (503A Category 1) | FDA-approved | Phase 2 clinical trials |
| Primary route studied | IV bolus/infusion | IV/SC; intranasal studied | IV/SC | IM/SC | SC |
| Tachyphylaxis risk | High (dose-dependent; days in chronic use) | Moderate (14-day window with twice-daily SC) | Low with pulsatile; high with continuous | Low | Under investigation |
| OHSS risk for IVF | Not studied (half-life too short) | Low (studied as IVF trigger) | Standard risk | High | Under investigation |
Kisspeptin-10 and Kisspeptin-54 bind to KISS1R with the same affinity in vitro (Kd ~1.9 nM). The difference is in vivo. Kisspeptin-54’s 27.6-minute half-life gives roughly 7 times longer exposure per dose than Kisspeptin-10’s 4 minutes — producing stronger, longer LH responses in clinical studies.
MVT-602 is a next-generation kisspeptin receptor agonist in Phase 2 clinical trials (ClinicalTrials.gov), designed with a longer duration of action to overcome the half-life limitations that restrict both native kisspeptin forms.
Dosing and administration
Important: No validated chronic outpatient protocol exists for Kisspeptin-10. All dosing data below reflects published research protocols, not prescribing recommendations. IV delivery was used in all published clinical trials. Kisspeptin-10 has no injury-site-specific mechanism — there is no rationale for injecting it near a joint or muscle.
| Goal | Sex | Route | Dose | Expected outcome | Evidence source |
|---|---|---|---|---|---|
| Diagnostic HPG axis testing | Male | IV bolus | 1.0 mcg/kg (~70 mcg for 70 kg man) | LH rise within 30 min; confirms HPG integrity | George et al., 2011 |
| Testosterone stimulation | Male | IV infusion | 1.5–4 mcg/kg per hour | LH pulse frequency increase; testosterone elevation | George et al., 2011 |
| HA acute stimulation | Female | SC injection | 6.4 nmol/kg | Acute LH increase (~24 IU/L on day 1) | Jayasena et al., 2009 |
| HSDD assessment | Both | IV infusion | 1 nmol/kg/h × 75 min | Brain activation changes; arousal measures | RCT, JAMA Network Open 2022–23 |
| TRT testicular preservation | Male | SC injection | 100–200 mcg, 2–3×/week | Theoretical LH maintenance | Vendor protocol only; no clinical data |
Route notes:
- IV delivery provides 100% bioavailability and was used in all published clinical trials
- Subcutaneous injection offers an outpatient option with slower onset and less predictable absorption
- Intranasal delivery has been studied for Kisspeptin-54 only — not Kisspeptin-10
- Oral administration is not viable for any kisspeptin form due to gastrointestinal peptide degradation
On chronic dosing: Twice-daily dosing causes tachyphylaxis within 14 days. Twice-weekly dosing partially preserves response over 8 weeks but still shows reduced effect compared to day 1.
Reconstitution and storage
For a typical 3 mg lyophilized vial, add 3 mL of bacteriostatic water to produce a 1 mg/mL concentration. Inject the water slowly along the inner vial wall and swirl gently until dissolved. Do not shake.
| State | Storage | Duration |
|---|---|---|
| Lyophilized (unreconstituted) | −20°C long-term; 2–8°C short-term | Per manufacturer |
| Reconstituted | 2–8°C, protected from light | 14–21 days |
Side effects and safety
In published clinical trials, Kisspeptin-10 has been generally well-tolerated for short-term use. No serious adverse events were reported in the George et al. (2011) study. A 2025 study in JCEM found no anxiogenic effect in humans, addressing earlier concerns from animal research.
Documented short-term side effects (from clinical trials)
| Side effect | Frequency | Severity | Route most associated | Resolution |
|---|---|---|---|---|
| Facial flushing | Common | Mild | IV bolus | Self-limiting (minutes) |
| Headache | Occasional | Mild | IV/SC | Self-limiting (hours) |
| Transient blood pressure change | Occasional | Mild | IV infusion | Self-limiting |
| Transient heart rate change | Occasional | Mild | IV infusion | Self-limiting |
| Injection site reaction | Occasional | Mild | SC | Self-limiting |
FDA-documented concerns (PCAC, October 2024)
The PCAC cited three categories of concern when voting unanimously against 503A compounding:
Tachyphylaxis. In women with HA receiving twice-daily Kisspeptin-54, the LH response fell by approximately 90% — from 24.0 to 2.5 IU/L — within 14 days (Jayasena et al., 2009). In primates, continuous high-dose Kisspeptin-10 infusion collapsed LH to baseline within 3 hours.
Immunogenicity. Peptide-based therapies carry an inherent risk of antibody formation with repeated dosing. No published kisspeptin study has specifically quantified immunogenicity in humans with long-term use.
Pro-atherosclerotic preclinical signal. Animal studies identified a potential pro-atherosclerotic effect. Its clinical relevance in humans is unknown. No cardiovascular adverse events have been reported in published human kisspeptin trials.
Contraindications
- Pregnancy (kisspeptin levels naturally rise 1,000- to 10,000-fold during pregnancy; effects of exogenous kisspeptin are unknown)
- Concurrent use of GnRH antagonists (direct pharmacological opposition)
- Concurrent testosterone replacement therapy (exogenous testosterone suppresses the HPG axis Kisspeptin-10 aims to stimulate)
- Active cardiovascular disease (precautionary, given the preclinical atherosclerosis signal)
Long-term safety gap: Most human kisspeptin trials lasted under 24 hours. The longest ran 56 days. Long-term safety data beyond that timeframe does not exist.
Legal status (2026)
Legal status: The FDA’s PCAC voted unanimously on October 29, 2024 against including Kisspeptin-10 on the 503A bulks list. Kisspeptin-10 remains a Category 2 bulk drug substance. Compounding pharmacies in the United States cannot legally prepare it for patient use. This is not a gray area.
The PCAC cited three rationales: insufficient history of compounding use, safety concerns (tachyphylaxis, immunogenicity risk, pro-atherosclerotic preclinical findings), and the absence of a USP monograph.
Kisspeptin-10 was not among the peptides anticipated for reclassification following the February 2026 HHS Secretary announcement. Several other peptides (BPC-157, Thymosin Alpha-1, AOD-9604) are expected to return to Category 1 status — Kisspeptin-10 is not among them.
Legitimate access: Kisspeptin-10 remains accessible only through clinical trials. Active trials include NCT05633966 and NCT03771326 on ClinicalTrials.gov. MVT-602, a kisspeptin receptor agonist, is in Phase 2 development.
Gray market risk: Vendors continue to sell Kisspeptin-10 labeled “for research use only” despite the PCAC decision. These products carry no purity, sterility, or identity guarantees.
WADA status: Kisspeptin-10 is not on the WADA 2026 Prohibited List as a specifically named substance. The WADA list is not exhaustive. Athletes should verify current status independently through GlobalDRO.com or USADA before using any peptide.
Alternatives to Kisspeptin-10
For most of the goals people associate with Kisspeptin-10, established alternatives exist with better clinical evidence and clearer regulatory pathways.
Testicular function preservation during TRT: hCG (human chorionic gonadotropin) is FDA-approved with decades of clinical data and a defined dosing protocol.
Female anovulation and infertility: Clomiphene citrate and letrozole are oral, inexpensive, and well-studied options with established clinical evidence.
Hypoactive sexual desire disorder (HSDD): Bremelanotide (Vyleesi/PT-141) carries FDA approval for this indication.
Gonadotropin stimulation and diagnostic HPG testing: GnRH analogs (gonadorelin, leuprolide) have defined regulatory pathways and extensive clinical evidence.
Kisspeptin-10’s legitimate clinical advantage is narrow but real. It provides upstream specificity for diagnosing HPG axis integrity — something direct LH or testosterone measurements cannot do alone. It preserves endogenous hormone production rather than replacing it, which distinguishes the kisspeptin pathway from direct hormone replacement.
Data gap: No published clinical data supports combining Kisspeptin-10 with BPC-157, TB-500, GHK-Cu, Sermorelin, CJC-1295, or Ipamorelin. These peptides operate through categorically different mechanisms. Theoretical synergy from unrelated pathways is not evidence.
Looking to explore peptide therapy for a reproductive health concern? A board-certified reproductive endocrinologist can evaluate your situation, order appropriate lab work, and discuss evidence-based options.
Frequently Asked Questions
Is Kisspeptin-10 FDA-approved?
No — and it cannot be legally compounded in the US either. The FDA’s PCAC voted unanimously on October 29, 2024 against including it on the 503A bulks list, citing safety concerns and insufficient compounding history. Access is limited to clinical research under investigational protocols.
What is the half-life of Kisspeptin-10?
Kisspeptin-10 has an IV plasma half-life of approximately 3.8–4 minutes. The peptide clears from the bloodstream within roughly 20 minutes. Downstream effects on LH and testosterone persist longer than the peptide itself. Kisspeptin-54 has a half-life of 27.6 minutes — approximately 7 times longer.
Can Kisspeptin-10 prevent testicular atrophy during TRT?
The mechanism is plausible — Kisspeptin-10 stimulates LH, which maintains Leydig cell activity and testicular volume. No published clinical trial has confirmed this specific use. Vendor protocols (100–200 mcg SC, 2–3 times per week) are not evidence-based. hCG is the established alternative for this purpose.
Can women use Kisspeptin-10?
Response depends heavily on menstrual cycle phase. Women in the follicular phase show no significant LH response even at high IV doses (10 nmol/kg). Women in the preovulatory and luteal phases respond with robust LH and FSH increases. Women with hypothalamic amenorrhea respond acutely, but tachyphylaxis develops within 14 days of twice-daily dosing.
Does Kisspeptin-10 show up on drug tests?
Kisspeptin-10 is not a named substance on the WADA 2026 Prohibited List, and standard drug panels do not test for kisspeptin. Athletes should independently verify current status before using any peptide, as the WADA list is non-exhaustive and regulatory classifications can change.
Why did higher doses produce a weaker response in clinical trials?
KISS1R — the receptor Kisspeptin-10 binds to — desensitizes rapidly with excess stimulation. In the George et al. (2011) trial, a 3 mcg/kg bolus produced a measurably weaker LH response than 1 mcg/kg. More is not more with this peptide.
What are natural ways to support kisspeptin function?
No supplement has been shown to directly increase kisspeptin production. Caloric restriction, extreme exercise, very low body fat, and chronic psychological stress all suppress kisspeptin neurons in the hypothalamus. Adequate caloric intake, sufficient sleep, and stress management support normal HPG axis function and endogenous kisspeptin signaling.
References
- George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228–E1236. PMID: 21632807.
- George JT, Veldhuis JD, Tena-Sempere M, Millar RP, Anderson RA. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol. 2013;79(4):550–558. PMID: 23153270.
- Jayasena CN, Nijher GMK, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315–4323. PMID: 19820030.
- Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667–3677.
- Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709–719.
- FDA Pharmacy Compounding Advisory Committee (PCAC). Meeting proceedings, October 29, 2024. Kisspeptin-10 review for 503A bulks list inclusion.
- Alliance for Pharmacy Compounding. PCAC votes against four nominated bulk drug substances. October 29, 2024.
- Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485–500.
Considering peptide therapy for a reproductive health concern? Speak with a licensed, board-certified reproductive endocrinologist who can evaluate your specific situation, order appropriate lab work, and discuss evidence-based options.
Disclaimer: PeptideRx provides physician-reviewed educational content about peptide therapy. PeptideRx does not provide medical advice, diagnosis, or treatment. Kisspeptin-10 is not FDA-approved for human therapeutic use. The FDA PCAC voted unanimously against inclusion of Kisspeptin-10 on the 503A bulks list on October 29, 2024. All dosing information reflects published research protocols, not prescribing recommendations. Consult a licensed healthcare provider before making any decisions about peptide therapy. Content medically reviewed [date]. Evidence grading criteria are working definitions pending formal review.